Loading…
← CockpitCompetitor Analysis › 688622.SS Guangzhou Hexin Instrument Co., Ltd. Class AOpen in the cockpit ↗

Guangzhou Hexin Instrument Co., Ltd. Class A688622.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese maker of mass spectrometry instruments for environmental monitoring, biomedicine, food safety and industry.

≈ A Chinese Thermo Fisher/Agilent for mass spectrometersMomentum leader 91
Mkt cap
$1.06B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$7.23M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-15.2 pp
WACC 8.5%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥100.15
1D-1.7%
1W-10.6%
1M-4.9%
3M-7.1%
6M+21.5%
YTD-1.0%
1Y-36.4%
ATR %8.1%
52w lowhigh36.9% off high

What Guangzhou Hexin Instrument does

Chinese maker of mass spectrometry instruments for environmental monitoring, biomedicine, food safety and industry.

Sells instruments mainly to government monitoring bodies and labs, often through public tenders, so orders follow government environmental and food-safety budgets. After-sales service and software add repeat revenue, while foreign makers still hold most of the high-end market.

In one line: A Chinese Thermo Fisher/Agilent for mass spectrometers.

Products and services

  • Mass spectrometers
  • Analytical software/services

Customers

  • Environmental monitoring agencies
  • Biomedical/food-safety labs
  • Industrial customers

Where it sits in the supply chain

  • Health Care
  • Scientific instruments
  • Mass spectrometry instruments

What could go right

  • Environmental monitoring instrument demand
  • Domestic-substitution in scientific instruments

What could go wrong

  • Competition from established global instrument makers

Moat: narrow (IP / patents, process know-how). Domestic mass-spec instrument know-how, though global majors dominate high-end segments.

Headquarters: Guangzhou, Guangdong, China · Founded: 2004 · Employees: 199

Named competitors

Guangzhou Hexin Instrument at a glance

Size Guangzhou Hexin Instrument (688622.SS) is a China Health Care company (Medical Specialties) with a market value of $1.06B, the 2041st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥100.15 on 18 Nov 2026.

Performance Over six months the shares gained 21.5%, against -8.9% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue fell 28.7% over the last twelve months (peer median +10.6%); the operating margin is -73.5% (peer median 17.4%).

Valuation It trades at 85.0× enterprise value to sales against a peer median of 4.0× (most expensive of 20).

Capital Return on invested capital runs 15.2 points below its cost of capital (8.5% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026688622.SS 127Peer median 92
Six months, rebased to 100: Guangzhou Hexin Instrument against the median of its 20 peers (local-currency closes).

Guangzhou Hexin Instrument financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥86.2MCN¥99.1MCN¥200MCN¥364MCN¥278M
Revenue growth—-50%-45%+31%—
Gross profitCN¥46.2MCN¥17.3MCN¥50.8MCN¥116MCN¥115M
EBITDAn/a-CN¥42.8M-CN¥41.9M-CN¥103M-CN¥91.4M
Net income-CN¥87.9M-CN¥94.8M-CN¥46.0M-CN¥96.1M-CN¥63.3M
Free cash flow-CN¥24.1M-CN¥24.6M-CN¥78.1M-CN¥145M-CN¥161M
Capital expenditureCN¥30.9MCN¥33.8MCN¥69.9MCN¥109MCN¥77.6M
Total debtCN¥311MCN¥281MCN¥285MCN¥356MCN¥249M

Quarterly statements and history in the cockpit →

Guangzhou Hexin Instrument competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%SIBN301101IRMDIART214150ATECCSTLEUZ6000553010216523DRTS300685300206300406CBLL6881613001437730688622.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Guangzhou Hexin Instrument is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×25×50×75×SIBN301101IRMDIARTATECEUZ600055301021300406CBLL688161300143688622.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guangzhou Hexin Instrument is the large dot.

Guangzhou Hexin Instrument competitors and peer comparison

Head to head with its named competitors (688622.SS vs TMO vs A vs 6951.T)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Guangzhou Hexin Instrument 688622.SS$1.06B+21%-29%-74%85.0×n/a
Thermo Fisher Scientific TMO$257B+53%+8%19%6.2×21.3%
Agilent Technologies A$50.0B+56%+9%24%7.1×23.3%
JEOL 6951.T$2.12B-2%-15%12%1.9×22.2%

How Guangzhou Hexin Instrument compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guangzhou Hexin Instrument against its 20 peers (data as of 18 Nov 2026)
Measure688622.SSPeer medianRank in peer set
1-month return-4.9%-6.0%10th highest of 21
6-month return+21.5%-8.9%5th highest of 20
Distance from 52-week high-36.9%-27.5%8th lowest of 21
Revenue growth (TTM)-28.7%+10.6%lowest of 19
Operating margin-73.5%17.4%lowest of 20
EV / Sales85.0×4.0×most expensive of 20
ROIC minus cost of capital-15.2 pp+3.2 pp4th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%85.0×n/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%4.3×n/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%6.3×8.8%+8.8%
IRadimed IRMDUnited States$1.05B-9%+11%32%11.1×18.5%+21.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%4.0×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%1.9×n/an/a
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%2.1×57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%2.7×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%3.0×n/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%11.1×50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%0.9×-4.0%+3.5%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%4.7×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%2.5×6.9%-2.9%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%5.8×1.7%+9.9%
Ceribell CBLLUnited States$995M+42%+31%-70%8.3×n/an/a
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%4.7×11.3%-3.5%
INKON Life Technology 300143.SZChina$985M-23%+22%12%3.1×10.7%+12.9%
Mani 7730.TJapan$965M-7%+10%30%3.9×3.3%+13.9%

Questions

Who are Guangzhou Hexin Instrument's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Agilent Technologies (A), Shimadzu (6951.T). The cockpit's measured peer set (industry) also includes SI-BONE (SIBN), Mingyue Optical Lens (301101.SZ), IRadimed (IRMD), Integra LifeSciences (IART), CLASSYS (214150.KS), Freenome (FRNM).
Is Guangzhou Hexin Instrument expensive compared with its peers?
On ev / sales it trades at 85.0× against a peer median of 4.0×, most expensive of 20 in its peer set.
How has Guangzhou Hexin Instrument stock performed?
Over six months to 18 Nov 2026 the shares returned +21.5% against -8.9% for the median peer; over one year -36.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.